Sorry to be so slow...Yahoo has been giving me fits...
Ernie, this is more of the same bone mets chat. Yahoo shut me out of our prior conv...
The latest Celetia Higano Cabo trial - an intended exploration of the bone tumor micro-environment would seem to be one of the more important of the recent additions - at least wrt further understanding of Cabo's bone effect.
"Official Title: A Pilot Study of the Effects of Cabozantinib (XL184) on Bone Turnover and the Microenvironment in Men With Non-Metastatic and Metastatic Castration-Resistant Prostate Cancer
Primary Outcome Measures:
•Change in urinary N-telopeptide (uNTX) [ Time Frame: Baseline and 6 weeks ] [ Designated as safety issue: No ]
Will be analyzed after log-transformation."
It appears data for primary endpoint should be gathered 6 weeks following final patient recruitment and analyzed after log-transformation. What's that mean?
Thanks for all your great replies, Ernie!